Proteomics

Dataset Information

0

Protein and Signaling Pathway Responses to rhIL-6 Intervention before Lobaplatin Treatment in Osteosarcoma Cells using Quantitative Phosphoproteome Analysis


ABSTRACT: IL-6 plays a pivotal role in the process of drug resistance to kinds of chemotherapeutics including lobaplatin. However, the underlying changes of phosphoproteins and related signaling pathways in the posttranslational modification level is still uncover. In our study, a quantitative phosphoproteome analysis of the responses to rhIL-6 & lobaplatin treatment was performed in osteosarcoma cells. Cells were divided into three goups: the control group, the lobaplatin group, and the rhIL-6 & lobaplatin group. Three biological replicates were performed in each group. A total of 3373 proteins and 12183 peptides was identified and quantified, of which 3232 phosphorylated proteins and 11358 phosphorylated peptides were obtained. Between the rhIL-6 & lobaplatin group and the lobaplatin group, twenty-three statistically differentially expressed phosphorylated peptides were identified. The characteristics of differentially expressed phophoproteins were analyzed by GO and KEGG enrichment, kinases of the phosphoproteins were predicted and protein-protein interaction was illustrated/demonstrated using STRING. Conservative motifs that surround the phosphorylated serine, threonine and tyrosine residues were analyzed using the Motif-x algorithm. Western blotting were performed to verify the differentially expressed phosphorylated FLNC and the signaling pathway it involved in. Immunohistochemistry staining showed that p-FLNC and its kinase AKT1 as well as ERK1/2 are positively expressed in the platinum-resistant specimens, while these proteins are negative or weak in those of platinum-sensitive specimens. In conclusion, p-FLNC and the MAPK signaling pathway plays a crucial role in the process of IL-6 induced chemoresistance in osteosarcoma. It is the first phosphoproteomic study which reveals the signature of IL-6 intervention before lobaplatin treatment in human osteosarcoma cells.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell

DISEASE(S): Bone Cancer

SUBMITTER: Qiong Ma  

LAB HEAD: Qiong Ma

PROVIDER: PXD025970 | Pride | 2022-02-17

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
1698_.msf Msf
1698_FeNTA_I.raw Raw
1698_FeNTA_II.raw Raw
1698_TiO2_I.raw Raw
1698_TiO2_II.raw Raw
Items per page:
1 - 5 of 5
altmetric image

Publications

Quantitative phosphoproteomic analysis reveals chemoresistance-related proteins and signaling pathways induced by rhIL-6 in human osteosarcoma cells.

Zhang Rui R   Wang Huan H   Li Erliang E   Wu Yonghong Y   Wen Yanhua Y   Li Chenyu C   Liao Bo B   Ma Qiong Q  

Cancer cell international 20211030 1


<h4>Background</h4>IL-6 plays a pivotal role in resistance to chemotherapeutics, including lobaplatin. However, the underlying mechanisms are still unclear. This study was to investigate the changes in phosphoproteins and their related signaling pathways in the process of IL-6-induced chemoresistance to lobaplain in osteosarcoma cells.<h4>Methods</h4>We performed a quantitative phosphoproteomic analysis of the response of SaOS-2 osteosarcoma cells to recombinant human IL-6 (rhIL-6) intervention  ...[more]

Similar Datasets

2021-02-25 | PXD021564 | Pride
2014-02-01 | E-GEOD-52644 | biostudies-arrayexpress
2011-03-01 | E-GEOD-23940 | biostudies-arrayexpress
2024-01-26 | PXD040814 | Pride
2024-04-01 | E-MTAB-13906 | biostudies-arrayexpress
2019-07-09 | E-MTAB-8064 | biostudies-arrayexpress
2021-11-23 | PXD027714 | Pride
2013-06-06 | E-GEOD-47676 | biostudies-arrayexpress
2015-12-19 | E-GEOD-76158 | biostudies-arrayexpress
2022-02-17 | PXD027844 | Pride